Cartagena Protocol

Introduction

The Cartagena Protocol on Biosafety is a significant international environmental agreement that addresses the safe handling, transport, and use of living modified organisms (LMOs) resulting from modern biotechnology. It is a supplementary agreement to the Convention on Biological Diversity (CBD) and aims to protect biological diversity from potential risks posed by genetically modified organisms (GMOs).

Background and Origin

• The Protocol was adopted on 29 January 2000 and entered into force on 11 September 2003, following ratification by 50 parties. It was named after Cartagena, Colombia, where it was originally intended to be adopted, though the final adoption took place in Montreal due to unresolved issues.
• It emerged from concerns about the rapid advancements in biotechnology and the possible adverse effects of LMOs on biodiversity and human health.
• The Protocol is the first multilateral treaty specifically dealing with the transboundary movement of LMOs.

Objectives

• The primary objective is to ensure an adequate level of protection in the safe transfer, handling, and use of LMOs that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health.
• It follows the precautionary approach outlined in Principle 15 of the Rio Declaration on Environment and Development, which advocates for preventive measures even when scientific certainty is lacking.

Scope and Coverage

• The Protocol governs the transboundary movement, transit, handling, and use of LMOs that could potentially harm biodiversity or human health.
• It does not cover pharmaceuticals for humans or products derived from LMOs like processed foods, which are regulated under other agreements.

Main Provisions

Advance Informed Agreement (AIA) Procedure

• A core mechanism of the Protocol, the AIA ensures that countries receive detailed information about LMOs before they are imported, allowing them to make informed decisions.
• The AIA process includes:

• Notification by the exporter with detailed LMO information.

• Acknowledgment of receipt by the importing country.

• Decision-making by the importer, which may approve, prohibit, or request more information.

• Review and possible revision of decisions.

Biosafety Clearing-House (BCH)

• An information-sharing platform established to facilitate the exchange of scientific, technical, environmental, and legal information related to LMOs.
• It assists parties in implementing the Protocol by providing transparency and access to data on LMOs.

Significance and Impact

• The Protocol represents a harmonized international framework to manage biosafety risks associated with LMOs, balancing technological advancement with environmental and human health protection.
• It supports sustainable development by ensuring that biotechnology’s benefits do not come at the expense of biodiversity loss or health hazards.
• The precautionary principle embedded in the Protocol empowers countries, especially developing nations, to regulate LMOs based on risk assessments rather than waiting for conclusive scientific proof of harm.

Cartagena Protocol and India

• India ratified the Protocol in 2003 and is an active party.
• The Ministry of Environment, Forest and Climate Change (MoEF&CC) serves as the Competent National Authority responsible for its implementation.
• India has developed a robust biosafety regulatory framework since 1989, with guidelines for risk assessment and management of GMOs, which are synonymous with LMOs in Indian regulations.
• The Protocol complements India’s existing biosafety laws and supports its efforts to regulate biotechnology safely.

Download as PDF